Sabrina Arena

Medicine · Health Sciences

35h-index7.2kcitations251works1.82yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(92), Lung Cancer Treatments and Mutations(48), DNA Repair Mechanisms(41), Cancer Genomics and Diagnostics(37), Genetic factors in colorectal cancer(34)

Publications251 total

Preoperative circulating cell-free DNA as predictor of postoperative complications after primary and interval cytoreductive surgery for advanced ovarian cancer
International Journal of Gynecological Cancer·2026
Exploiting patient-derived models to unveil replication stress vulnerabilities as effective therapeutic targets in gynecological cancers
International Journal of Gynecological Cancer·2026
Diagnostic value of baseline circulating cell-free DNA and circulating tumor cells for predicting peritoneal disease burden in advanced ovarian cancer: preliminary results of a prospective pilot study
International Journal of Gynecological Cancer·2026
Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial
ESMO Open·2025Open Access
IUC22021-72 The inside study: innovative preclinical models for precision medicine in advanced prostate cancer
The Oncologist·2025Open Access
Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells
Nature Communications·2025· 1 citedOpen Access
Early-Onset Colorectal Cancers Exhibit Distinctive Placental-Like Features
2025Open Access
Figure S5 from Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations
2025Open Access
Figure S4 from Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations
2025Open Access
Figure S9 from Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations
2025Open Access
Figure S12 from Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations
2025Open Access
Figure S8 from Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations
2025Open Access
Figure S3 from Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations
2025Open Access
Figure S7 from Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations
2025Open Access
Figure S2 from Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations
2025Open Access
Figure S6 from Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations
2025Open Access
Figure S1 from Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations
2025Open Access
Figure S10 from Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations
2025Open Access
Figure S11 from Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations
2025Open Access
Data from Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations
2025Open Access
page 1 of 13Next →

Frequent Co-authors

Alberto Bardelli(41), Federica Di Nicolantonio(23), Salvatore Siena(19), Andrea Sartore‐Bianchi(17), Simona Lamba(12), Carlotta Cancelliere(9), Mariangela Russo(8), Luca Lazzari(8), Annalisa Lorenzato(7), Giorgio Corti(7), Gianluca Mauri(7), Monica Montone(6), Livio Trusolino(6), Alessio Amatu(6), Giulia Siravegna(6), Erika Durinikova(6), Miriam Martini(5), Pamela Arcella(5), Benedetta Mussolin(5), Silvia Marsoni(5)